Also, the relationship between OCs use and specific subtypes of breast cancer [Estrogen Receptor-Positive (ER+), Estrogen Receptor-Negative (ER-), Human Epidermal growth factor Receptor 2-Positive (HER2+), Progesterone Receptor-Positive (PR+)] should be evaluated. This evidence concerns the gene ESR1 and breast carcinoma.